Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date
about
Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonistImpact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.Antidepressant actions of ketamine: from molecular mechanisms to clinical practiceInnovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?A brief history of the development of antidepressant drugs: from monoamines to glutamateHomer1/mGluR5 activity moderates vulnerability to chronic social stressThe role of ventral striatal cAMP signaling in stress-induced behaviors.Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology reviewRole of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesGlutamate and its receptors in the pathophysiology and treatment of major depressive disorderEpigenetic Activation of ASCT2 in the Hippocampus Contributes to Depression-Like Behavior by Regulating D-Serine in Mice.Increased Glutamate in Somatosensory Cortex in Functional DyspepsiaThe Emerging Role for Zinc in Depression and Psychosis.Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects.Antidepressant effect of ketamine in sub anaesthetic doses in male albino miceMicroglial dysregulation in psychiatric diseaseNeuronal nitric oxide synthase (NOS1) polymorphisms interact with financial hardship to affect depression riskBeyond serotonin: newer antidepressants in the future.Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes.Transcutaneous auricular vagus nerve stimulation triggers melatonin secretion and is antidepressive in Zucker diabetic fatty ratsEvidence for alterations of the glial syncytial function in major depressive disorder.Screening for AMPA receptor auxiliary subunit specific modulators.Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depressionUnderstanding resilience.Human biomarkers of rapid antidepressant effectsGlutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.Current status of ketamine and related compounds for depressionEpilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)GluN3A: an NMDA receptor subunit with exquisite properties and functions.Ketamine as antidepressant? Current state and future perspectives.Increased PKC activity and altered GSK3β/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Leading compounds for the validation of animal models of psychopathology.Novel glutamatergic drugs for the treatment of mood disorders.Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.NMDA antagonists under investigation for the treatment of major depressive disorder.Perisynaptic astroglial processes: dynamic processors of neuronal information.Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.Current Evidence of Chinese Herbal Constituents with Effects on NMDA Receptor Blockade.Involvement of glutamatergic neurotransmission in the antidepressant-like effect of zinc in the chronic unpredictable stress model of depression.
P2860
Q26750021-0F2BB013-DFD2-4C58-93EE-A5D795F52A03Q26830533-C871C282-13BE-4A4F-B37E-918A1FB7C624Q26995879-C2541A3B-A353-49F7-B0D4-6C3D17DFA0BAQ26996411-3993073F-E895-485C-8ABA-8C2C1CCD5AD0Q27028050-45EFE0EB-633E-4C2D-8CD8-5D0186BB0BCEQ27311111-C7BCF889-43DA-4390-A046-32471AE1C90AQ27312156-454EEBAC-54EA-4CA8-B3BB-00BED6EE9AC5Q28067988-BDA5A2FE-C2E2-4D15-B21F-76A1A4BDEB16Q28072353-0DE31F8D-0FEF-4A0E-B600-6BE31BA24737Q30711088-67318988-CF92-4C63-883F-2F802D8DC84EQ33650476-45AF5A7A-085C-48C8-B5E9-C617E810AA4CQ33818965-E6370790-048C-4324-B1A1-2E753F858932Q33857369-24416693-F961-425E-8750-281CB4D4AE45Q33874356-91C20332-F48D-4514-81A2-F3B1CA88793EQ34030230-7587CCD9-1D56-4622-9AAE-D1EE56ADA2A8Q34345744-D741C220-E905-4A54-A1F8-F77F2CA54656Q34357009-FAF6291F-EAA8-42A8-AE62-093A4AEFFC78Q34557706-2D1ED697-C701-4E40-9C41-85C1E77FABC5Q34878452-FCC83FFD-2F79-4EFE-9BF1-39192CA94385Q35367511-A14B0E0E-B009-468B-826E-633E47496193Q35828185-05312D35-F7BF-49D8-AF74-555E7799CA7CQ36328451-6848813B-9BF8-4505-ACAE-54547912A50CQ36417179-A02BE325-7B9E-4CAB-B83F-C55EA343CBB1Q36612228-56BEE2B1-E05A-4719-BCB8-71A3E908FCABQ36902074-DB9EAA4B-2AC3-4052-9BD9-F930C91E7EBDQ37121338-47A7BC7C-04AF-4CDD-99E8-37A3700CDC02Q37202885-DFFC3525-D0E3-44EE-9153-CB0B21D75044Q37242260-27D3E043-82CE-4B89-9F7E-A137EA9A7FE5Q37412890-44D40CC8-E3F7-47BF-BD96-3DBEDA3C4576Q37559823-C20B3ACC-588F-4311-87F6-1073819E6BD7Q37668134-7E03C0B8-DE64-412C-A160-500FF742C8A1Q38123516-2BA662DE-A29D-41B5-9B53-9611EA420A18Q38128733-DF0B3DD0-F49D-421E-80C8-4B1BD919FA51Q38131480-3F9DD134-5590-4AC0-9B32-69EFF7445986Q38157027-BEE262FD-3CF2-4394-8B49-BA4D67390F0CQ38211107-53AF041C-BCFF-4A95-B8CD-9ACE35CB3DA9Q38508710-CBDDD24E-AEA1-4E81-86DD-E82F4034447AQ38924066-A085E4A9-E51B-428B-A200-65AE9DCD3EBDQ39307652-C0BBE15A-262D-4806-A92B-C053816798AFQ40127644-39B8C870-7F69-40E9-83CE-6EF0FEA8849C
P2860
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting the glutamatergic sy ...... rationale and progress to date
@ast
Targeting the glutamatergic sy ...... rationale and progress to date
@en
Targeting the glutamatergic sy ...... rationale and progress to date
@nl
type
label
Targeting the glutamatergic sy ...... rationale and progress to date
@ast
Targeting the glutamatergic sy ...... rationale and progress to date
@en
Targeting the glutamatergic sy ...... rationale and progress to date
@nl
prefLabel
Targeting the glutamatergic sy ...... rationale and progress to date
@ast
Targeting the glutamatergic sy ...... rationale and progress to date
@en
Targeting the glutamatergic sy ...... rationale and progress to date
@nl
P2860
P3181
P1433
P1476
Targeting the glutamatergic sy ...... rationale and progress to date
@en
P2093
Carlos A Zarate
Daniel C Mathews
P2860
P304
P3181
P356
10.2165/11633130-000000000-00000
P407
P577
2012-07-01T00:00:00Z
P5875
P6179
1046184655